Short Interest in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Decreases By 50.7%

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) was the recipient of a large decline in short interest during the month of December. As of December 15th, there was short interest totalling 59,600 shares, a decline of 50.7% from the November 30th total of 120,900 shares. Approximately 0.2% of the shares of the company are sold short. Based on an average daily volume of 149,700 shares, the days-to-cover ratio is currently 0.4 days.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Bolt Biotherapeutics stock. FMR LLC grew its position in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) by 33.2% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 115,386 shares of the company’s stock after acquiring an additional 28,773 shares during the quarter. FMR LLC owned 0.30% of Bolt Biotherapeutics worth $75,000 as of its most recent SEC filing. Institutional investors and hedge funds own 86.70% of the company’s stock.

Bolt Biotherapeutics Stock Performance

Shares of Bolt Biotherapeutics stock traded up $0.01 during trading on Friday, reaching $0.52. The company’s stock had a trading volume of 257,086 shares, compared to its average volume of 167,273. The business’s fifty day moving average price is $0.59 and its 200-day moving average price is $0.66. Bolt Biotherapeutics has a one year low of $0.48 and a one year high of $1.56. The firm has a market cap of $19.83 million, a price-to-earnings ratio of -0.30 and a beta of 0.93. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.16 and a current ratio of 3.16.

Bolt Biotherapeutics (NASDAQ:BOLT) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.04). Bolt Biotherapeutics had a negative net margin of 665.56% and a negative return on equity of 69.46%. The business had revenue of $1.14 million during the quarter, compared to the consensus estimate of $1.02 million. As a group, equities research analysts predict that Bolt Biotherapeutics will post -1.61 earnings per share for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Bolt Biotherapeutics in a report on Wednesday, November 13th. Five investment analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $3.50.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.